Pharmaron Beijing Co., Ltd. (FRA:17Q1)

Market Cap	6.26B +12.4%
Revenue (ttm)	1.72B +14.8%
Net Income	202.61M -7.2%
EPS	0.11 -7.1%
Shares Out	n/a
PE Ratio	30.91
Forward PE	23.93
Dividend	0.02 (1.05%)
Ex-Dividend Date	Jul 4, 2025

Volume	n/a
Average Volume	222
Open	2.200
Previous Close	2.240
Day's Range	2.200 - 2.200
52-Week Range	1.480 - 3.240
Beta	n/a
RSI	50.89
Earnings Date	Mar 30, 2026

About Pharmaron Beijing

Pharmaron Beijing Co., Ltd., together with its subsidiaries, operates as a pharmaceutical research and development service platform in North America, Europe, the Mainland China, Asia, and internationally. It operates through five segments: Laboratory Services; Chemical and Formulation Process Development and Manufacturing Services; Clinical Research Services; Macromolecule and Cell and Gene Therapy Services; and Others. The company offers laboratory chemistry and biological science services, including small molecule chemical drugs, oligonucleot...

• Industry: Commercial Physical and Biological Research
• Founded: 2004
• Employees: 25,088
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 17Q1

Financial Performance

In 2025, Pharmaron Beijing's revenue was 14.10 billion, an increase of 14.82% compared to the previous year's 12.28 billion. Earnings were 1.66 billion, a decrease of -7.22%.

Financial numbers in CNY